Last reviewed · How we verify
DA-3801 Injection
DA-3801 is a recombinant human growth hormone analog designed to promote growth and metabolic effects.
DA-3801 is a recombinant human growth hormone analog designed to promote growth and metabolic effects. Used for Growth hormone deficiency (in development).
At a glance
| Generic name | DA-3801 Injection |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | Growth hormone analog |
| Target | Growth hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
DA-3801 functions as a growth hormone secretagogue or growth hormone analog that stimulates growth hormone signaling pathways. It is being developed for therapeutic applications where growth hormone supplementation or stimulation may provide clinical benefit, particularly in conditions involving growth deficiency or metabolic dysfunction.
Approved indications
- Growth hormone deficiency (in development)
Common side effects
- Injection site reactions
- Headache
- Arthralgia
Key clinical trials
- A Phase III Clinical Study to Compare the Efficacy and Safety of DA-3801 and That of Gonal-F® (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-3801 Injection CI brief — competitive landscape report
- DA-3801 Injection updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI